Glucocorticoids are an effective treatment for croup, although the most beneficial route of administration remains unclear. Recent studies have concluded that both intramuscular dexamethasone and oral dexamethasone are effective treatments, but there are few data directly comparing the two for moderate-to-severe croup. Objectives: The authors' primary objective was to determine whether there is a difference in proportion of children with resolution of symptoms attributable to croup at 24 hours, when treated with oral or intramuscular dexamethasone. Secondarily, the authors sought to estimate whether there is a difference in proportion of children with resolution of symptoms attributable to croup at 10 days and to estimate the interval to complete resolution of symptoms between these two routes. Methods: The authors performed a prospective, randomized, doubleblind trial involving children aged 3-84 months with moderate-to-severe croup, presenting to a suburban teaching emergency department (ED). Patients were eligible for enrollment if they had inspiratory stridor or a barky cough and a croup score of 2 or greater after 10-15 minutes of cool mist therapy. The patients were randomized to one of two intervention groups. In both groups, the parents were not present in the treatment room during study drug administration. One group received 0.6 mg/kg of intramuscular dexamethasone and an oral placebo, while the other group received 0.6 mg/ kg of oral dexamethasone and direct pressure on their thigh with the hub of a syringe. A nurse placed a BandAid on the site of the real or mock injection. Parents were contacted by telephone approximately 1 and 10 days after the index visit to ask about their child's symptoms using a standardized questionnaire. Data were analyzed using an intention-to-treat approach. Results: Of 126 patients eligible, 96 were recruited, with complete follow-up on 95. The groups were similar in all baseline characteristics, treatments received in the ED, and disposition. At 24 hours and 10 days after the visit, there were no statistical differences between the groups for the proportion with stridor, expiratory sounds, barky cough, sleep pattern, the degree of improvement, or the proportion with complete resolution of symptoms at one day. Conclusions: No statistical differences for any parameters were observed between intramuscular and oral dexamethasone treatments for children with moderateto-severe croup at 24 hours or at any time the week after treatment. The durations of symptoms were similar between the treatment groups.
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14 Patients with croup who improve after treatment with racemic epinephrine, dexamethasone, and cool mist may be safely discharged home after three hours of observation. 15 Intramuscular (IM) dexamethasone versus placebo has been shown to confer a benefit in reducing symptoms. 4, 6 A recent meta-analysis of 24 studies concluded that dexamethasone and inhaled bude- sonide are effective in relieving the symptoms of croup as early as six hours after treatment. 14 Nebulized budesonide has been compared with oral dexamethasone, with similar outcomes. 9 However, when IM dexamethasone is compared directly with nebulized budesonide, IM dexamethasone results in more rapid improvement. 7 To the best of our knowledge, the only study directly comparing IM dexamethasone with oral dexamethasone for the treatment of moderate-tosevere croup was reported by Rittichier and Ledwith. 16 This study, which was published after the completion of our trial, found no difference in outcomes between IM and oral dexamethasone for the outpatient management of moderate croup. However, this study included children with mild croup.
We performed a prospective randomized, double-blind trial comparing IM and oral administrations of dexamethasone for the treatment of moderate-to-severe croup to determine whether there is a difference in proportion of children with resolution of symptoms attributable to croup at 24 hours after treatment. Secondarily, we sought to estimate whether there is a difference in proportion of children with resolution of symptoms attributable to croup at 10 days and to estimate the interval to complete resolution of symptoms between these two routes.
METHODS
Study Design. We performed a prospective, randomized, double-blind trial. We obtained outcome data by contacting the parents by phone 1 day and 7-10 days after the index visit. We used a standardized questionnaire to query parents as to the symptoms their child was still experiencing, whether they sought any further evaluation, what treatment they thought their child received in the emergency department (ED), and their level of satisfaction with the ED treatment. The William Beaumont Hospital Human Investigations Committee approved this study.
Study Setting and Population. Children were eligible if they were ages 3 to 84 months, had a history of inspiratory stridor or a barky cough, and had a croup score of 2 or greater utilizing the Westley scoring system (Table 1) , 17 after 10 to 15 minutes of cool mist therapy. Patients were excluded if their croup score was less than 2 because treatment of such mild symptomatic croup could potentially dilute the treatment effect. Additional exclusion criteria included signs suggesting another cause for stridor such as epiglottitis, bacterial tracheitis, foreign body, or chronic lung disease; severe co-morbidities; inability of the parents to give informed consent; or glucocorticoid therapy within four weeks of presentation. Dedicated emergency pediatric nurses obtained the croup score. In a 1994 preliminary unpublished study, we observed excellent agreement in croup scores between emergency physicians and nurses, with a kappa of 0.86, which is similar to that reported by Johnson and colleagues. 7 We performed this study at the Emergency Department of William Beaumont Hospital from January 1, 1999, to December 31, 1999. This is a 929-bed suburban, university-affiliated teaching hospital, with more than 100,000 annual ED visits, 25% of which are by children 18 years old or younger. Emergency medicine faculty both primarily treat and directly supervise the care of all children in the pediatric emergency section of the ED. They supervise emergency medicine, pediatric, and family practice residents.
Study Protocol. After written informed consent was obtained from the patient's parents, the patient was randomly assigned to one of two intervention groups, using a block randomization method from a random number generator performed by the Department of Pharmacy. Packets of the study drugs were stored in the locked Pyxis system (Pyxis Corporation, San Diego, CA) within the pediatric ED.
In both groups neither the parents nor the treating physicians were present in the treatment room during administration of medications. The IM group received 0.6 mg/kg of IM dexamethasone in their thigh and an oral placebo (Ora-Sweet syrup, Paddock Laboratories, Inc., Minneapolis, MN). The ORAL treatment group received 0.6 mg/kg of oral dexamethasone and direct pressure with the hub of a syringe on their thigh. Children in both treatment groups received a Band-Aid on their thigh. If the child vomited while in the ED, the treatment given was unblinded and, if in the ORAL group, he or she was given a dose of IM dexamethasone. We chose equal doses of dexamethasone to limit dose-induced variability, as the bioavailability of oral dexamethasone is quite good: 78% Ϯ 14%. 18 The hospital pharmacy prepared the oral medication by using Dexamethasone Intensol Solution (Roxane Laboratories, Columbus, OH), which has a concentration of 1 mg/1 m placed in Ora-Sweet syrup. The emergency medicine faculty made all decisions regarding the need for additional treatment such as racemic epinephrine and hospitalization based on their clinical judgment on an individual-case basis and were blinded as to the route of administration of the drug. All children received 10 to 15 minutes of cool mist therapy via a plastic tube held by their parents to the patient's face before they were deemed eligible for the study. One author (RGP) telephoned the parents of the children who were not hospitalized, personally interviewed the hospitalized patients' parents, and was blinded to the treatment allocation. Follow-up contacts were done at approximately 24-48 hours and again at approximately 10 days. Each set of parents was asked the same follow-up questions in the same order.
Outcome Measures. The main outcomes measured were the proportion of symptoms resolved at 24 hours. We believed that the outcomes used in previous studies, such as ED length of stay, rate of hospitalization, seeking additional care, or use of racemic epinephrine, are confounded by practice patterns of emergency physicians, practice patterns of pediatricians, parental concerns, adequacy of the home care situation, and the availability of beds within the ED and pediatric wards. We did, however, collect this information. The degree of improvement was measured by a five-point ordinal scale: worse = 1, the same = 2, somewhat better = 3, much better = 4, and completely better = 5. We also specifically asked about the presence of inspiratory and expiratory sounds, whether they sought additional treatment, return to normal sleeping patterns, and whether the parents thought their child received the IM or oral medication. Information such as duration of symptoms, fever, home treatment, ED treatment, and the patient's disposition were collected while the patient was in the ED.
Data Analysis
all symptoms at one day was based purely on gross estimates, as we could not find prior studies that measured our designated primary outcome. Assuming a proportion of 0.5 for symptom resolution, and that a 20% difference in outcome would be clinically significant, we estimated a sample size of 206 to obtain a power of 0.8. We planned an interim analysis after 100 cases.
RESULTS
During the one-year study period, our department treated 397 patients in 409 visits with the final diagnosis of croup. Of these visits, 33 patients were not eligible, because they were outside the age range, and 217 were excluded because they had mild croup. An additional 17 had steroids before arrival to the ED, 12 refused to participate, in 3 cases the study drug was not available, and 2 patients had a concomitant serious illnesses. Of the remaining 125 visits in which the child was potentially eligible, our faculty successfully enrolled 96, with complete follow-up information on 95. No child was enrolled twice. There were no statistically significant differences between the IM and ORAL groups for age, duration of symptoms, temperature, initial croup score, past history of croup, sex, home treatments, past history of asthma, treatment with racemic epinephrine, need for x-ray, or admission to hospital (Table 2) . Additionally, there were no statistically significant differences in baseline characteristics between the 95 children in the study cohort and those 30 not recruited, demonstrating no selection bias.
At 24 hours there were no statistical differences between groups for the proportion with stridor, expiratory sounds, barky cough, sleeping patterns, and the degree of improvement. Only five had complete resolution of symptoms at 24 hours, 1 (2%; 95% CI = 0.1% to 10%) in the ORAL group and 4 (8%; 95% CI = 3% to 18%) in the IM group (Tables  3 and 4) . No child who was discharged home in either group returned to the ED as a treatment failure. Because of these findings, we terminated the study as our estimates for event rate in our initial sample size determination were off by an order of magnitude. After 10 days, 2 patients still experienced stridor, 2 still had some expiratory sounds, 2 had a barky cough, all but 3 were able to sleep through the night, and only 1 was reported to have not improved. At 10 days after the visit, there were no statistical differences between groups for the proportion with stridor, expiratory sounds, barky cough, need for additional evaluation or treatment, the degree of improvement, or the duration to complete resolution of symptoms. Both groups required a median of 4 days to attain complete resolution of symptoms according to the parents. At day 4, 26 (59%; 95% CI = 43% to 71%) in the ORAL group and 27 (53%; 95% CI = 39% to 65%) in the IM group had complete resolution of symptoms.
DISCUSSION
In this prospective, randomized, double-blind trial involving children with moderate-to-severe croup, we observed no difference in the degree of improvement at 24 hours between those patients receiving IM dexamethasone and those receiving oral dexamethasone. Furthermore, there was no statistical difference between the two groups with regard to persistent stridor, expiratory sounds, barky cough, return to normal sleeping pattern, and parent assessment of improvement.
It is well accepted that IM dexamethasone hastens recovery compared with placebo. 4, 5 Cruz et al. investigated 38 patients in a double-blind, randomized, placebo-controlled trial observing a reduction in the severity of illness within 24 hours after treatment with IM dexamethasone. 6 Several meta-analyses have concluded that steroids are beneficial in the treatment of croup. 14, 19 In children with moderately severe croup, treatment with IM dexamethasone or nebulized budesonide resulted in more rapid clinical improvement than did the administration of the placebo, with dexamethasone offering the greatest improvement. 7 The above trials all revealed a clinical improvement in those children receiving IM dexamethasone. Geelhoed and Macdonald reported that oral dexamethasone in a dose of 0.15 mg/kg is as effective as 0.3 or 0.6 mg/kg for reducing stridor and retractions within 8 hours of dosing. 2, 3 However, the course of long-term recovery was not measured in this trial. In a trial of 100 patients, oral dexamethasone in a dose of 0.15 mg/ kg was effective in reducing the return to medical care with ongoing mild croup. 8 The only outcome measure used by the investigators was necessity to return for medical care, leaving uncertain the condition of those not seeking further care. The Westley croup score, hospital admission rates, time spent in the ED, and ongoing symptoms were all assessed in a three-arm trial comparing oral dexamethasone (0.6 mg/kg) and nebulized placebo; oral placebo and nebulized budesonide (2 mg); and oral dexamethasone (0.6 mg/kg) and nebulized budesonide (2 mg). Similar outcomes were measured in the three groups, concluding no difference between oral and nebulized steroids. 9 Again, these trials suggest improvement with oral dexamethasone in the treatment of croup.
Though the use of steroids is well accepted, there exists a great deal of practice variability in the dose and route of administration. A survey regarding the use of corticosteroids for the treatment of croup in 1994 demonstrated that most physicians surveyed were using steroids to treat both hospitalized and non-hospitalized patients with croup. The form of the drug used, dosing regimen, and route of administration were all highly variable. 20 Since 1994 there have been several clinical trials and metaanalyses, as listed above, focusing on the amount of steroids, the route administered, and the combination with other treatment adjuncts such as racemic epinephrine. 21 In 2000, Rittichier and Ledwith used similar outcome parameters and had results similar to those in our study. 16 However, they included patients without symptoms or signs in the ED and those with severe croup requiring inpatient management. Although both studies found no statistical difference between oral and IM administrations of dexamethasone, we included the children with severe croup and those requiring admission. Our average croup score was 3.5, as compared with Rittichier and Ledwith's study, in which the croup score was 2.
Perhaps our most telling observation is that croup, though self-limited, does not have particularly short course. In both the IM and ORAL groups, only half of the children were completely better at the fourth night after the index visit.
In our study of IM and oral dexamethasone, we observed similar efficacies in the treatment of moderate-to-severe croup. There were two deviations from the protocol, both relating to children who had vomited the oral medication. These two patients were subsequently given IM dexamethasone and were discharged home, with symptoms fully resolving at 2 and 5 days. An important aspect concerning the validity of our study design and observations made was that the parents, who assessed outcomes, were truly blinded, as only 23% guessed the correct treatment that their child received.
LIMITATIONS
Our sample size is too small to find a statistically significant result for our primary outcome measure. At the time of study design, we did not have the luxury of preliminary data for sample size estimate with our primary outcome measure. We did not utilize hospitalization as the primary outcome, as that is a multifactorial decision made by the physician that may not be related to the intervention studied. Our sample size was also limited by our decision to exclude children with low croup scores.
We did this for two reasons: 1) to avoid a potential dilution of treatment effect as the severity and duration of symptoms in these children are less, with potentially a less measurable benefit from steroids; and 2) our current practice pattern for use of steroids in mild croup is inconsistent and we could not ethically justify including these children in a trial. Indeed, of 228 children with mild croup, 87 received IM dexamethasone, 49 received an oral steroid preparation, and 92 did not receive any steroid. We did not prospectively gather data on characteristics, treatments, and outcomes of patients not enrolled in the study. Perhaps a significant number of these patients were excluded in a systematic fashion, resulting in a bias. It is also possible that our observation will not apply to children with severe croup, as most of our cohort was classified as having moderately severe croup. These results cannot be generalized to the use of oral prednisone or prednisolone.
We did not distinguish between viral and spasmodic croup, as we think this neither can be reliably done nor would make a difference in treatment decisions. We did not exclude cases with prior intubation and realize that these children were at risk for subglottic stenosis. Both of the children who had a history of intubation were randomized to the ORAL group and were discharged home with improved croup scores. They both had complete resolution of symptoms within three nights.
We did not train or assess the ability of the parents to reliably assess the outcome measures. Perhaps our finding of no difference between groups is related to the variability of assessment between parents. However, an independent assessment was logistically and financially prohibitive. Realistically, are not the parents always the final arbitrator of the success or failure of a treatment?
